Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Saved in:
Bibliographic Details
Title: Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Authors: Gillessen S; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biosciences, Lugano, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland. Electronic address: silke.gillessen@eoc.ch., Murphy L; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., James ND; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK., Sachdeva A; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie Hospital NHS Foundation Trust, Manchester, UK., El-Taji O; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie Hospital NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UK., Abdel-Aty H; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK., Adler AI; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK., Amos C; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Attard G; University College London Cancer Institute, London, UK; University College London Hospitals, London, UK., Varughese M; Royal Devon University Hospitals NHS Foundation Trust & University of Exeter, Exeter, UK., Gale J; Queen Alexandra Hospital, Portsmouth, UK., Brown S; Oncology, Airedale General Hospital, Keighley, UK., Srihari N; Royal Shrewsbury Hospital, Shrewsbury, UK., Birtle AJ; Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston UK; University of Manchester, Manchester, UK; University of Central Lancashire, Preston, UK., Brown M; Division of Cancer Sciences, University of Manchester, Manchester, UK., Chan K; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Chowdhury S; Guy's and St Thomas' NHS Foundation Trust, London, UK., Cross W; St James's University Hospital, Leeds, UK., Dearnaley DP; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK; Royal Marsden NHS Foundation Trust, London, UK., Din O; Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Dutey-Magni P; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gilbert DC; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gilson C; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK., Gray S; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie Hospital NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UK., Grist E; University College London Cancer Institute, London, UK., Hofmann U; Calderdale and Huddersfield NHS Trust, Halifax, UK., Hudson AM; The Christie Hospital NHS Foundation Trust, Manchester, UK., Jain Y; The Christie Hospital NHS Foundation Trust, Manchester, UK., Jeyasangar G; Department of Oncology, Airedale General Hospital NHS Foundation Trust, Keighley, UK., Jones R; School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Kayani M; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Langley RE; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Malik Z; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Mason MD; School of Medicine, Cardiff University, Cardiff, UK., Matheson D; Faculty of education Health and Wellbeing, University of Wolverhampton, Walsall, UK., McAlpine C; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Macnair A; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Millman R; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Murphy C; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Padden-Modi M; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; The Institute of Cancer Research and The Royal Marsden Hospital, London, UK., Parikh O; Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust, Blackburn, UK., Parker C; Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK., Rush H; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Russell M; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Srinivasan R; Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK., Sundar S; Nottingham University Hospitals NHS Trust, Nottingham, UK., Tanguay JS; Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK., Turco F; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland., Williams P; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Sydes MR; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Parmar MKB; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Brown LC; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Clarke NW; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie Hospital NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UK.
Corporate Authors: STAMPEDE investigators
Source: The Lancet. Oncology [Lancet Oncol] 2025 Aug; Vol. 26 (8), pp. 1018-1030. Date of Electronic Publication: 2025 Jul 07.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(25)00231-1